AIM:IDH

Stock Analysis Report

Immunodiagnostic Systems Holdings

Executive Summary

Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally.


Snowflake Analysis

Flawless balance sheet with acceptable track record.


Similar Companies

Share Price & News

How has Immunodiagnostic Systems Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: IDH has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-2.9%

IDH

1.0%

GB Medical Equipment

1.4%

GB Market


1 Year Return

41.3%

IDH

31.4%

GB Medical Equipment

12.4%

GB Market

Return vs Industry: IDH exceeded the UK Medical Equipment industry which returned 32.4% over the past year.

Return vs Market: IDH exceeded the UK Market which returned 12.7% over the past year.


Shareholder returns

IDHIndustryMarket
7 Day-2.9%1.0%1.4%
30 Day-2.9%4.5%2.0%
90 Day-5.4%6.8%8.8%
1 Year41.9%41.3%33.8%31.4%18.3%12.4%
3 Year11.9%9.3%43.6%36.1%23.8%8.0%
5 Year-17.5%-20.9%72.9%58.2%41.8%8.9%

Price Volatility Vs. Market

How volatile is Immunodiagnostic Systems Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Immunodiagnostic Systems Holdings undervalued compared to its fair value and its price relative to the market?

68.29x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: IDH (£2.73) is trading above our estimate of fair value (£0.23)

Significantly Below Fair Value: IDH is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: IDH is poor value based on its PE Ratio (70.3x) compared to the Medical Equipment industry average (34.4x).

PE vs Market: IDH is poor value based on its PE Ratio (70.3x) compared to the UK market (18.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate IDH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: IDH is good value based on its PB Ratio (1.4x) compared to the GB Medical Equipment industry average (3.4x).


Next Steps

Future Growth

How is Immunodiagnostic Systems Holdings forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

12.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Immunodiagnostic Systems Holdings has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Immunodiagnostic Systems Holdings performed over the past 5 years?

20.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: IDH has high quality earnings.

Growing Profit Margin: IDH became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: IDH has become profitable over the past 5 years, growing earnings by 20.5% per year.

Accelerating Growth: IDH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: IDH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-4.5%).


Return on Equity

High ROE: IDH's Return on Equity (2%) is considered low.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Immunodiagnostic Systems Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: IDH's short term assets (£48.1M) exceed its short term liabilities (£7.1M).

Long Term Liabilities: IDH's short term assets (£48.1M) exceed its long term liabilities (£4.3M).


Debt to Equity History and Analysis

Debt Level: IDH is debt free.

Reducing Debt: IDH has no debt compared to 5 years ago when its debt to equity ratio was 2.2%.

Debt Coverage: IDH has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: IDH has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: IDH has a high level of physical assets or inventory.

Debt Coverage by Assets: IDH's debt is covered by short term assets (assets are 1.0839488763137E+17x debt).


Next Steps

Dividend

What is Immunodiagnostic Systems Holdings's current dividend yield, its reliability and sustainability?

0.26%

Current Dividend Yield


Dividend Yield vs Market

company0.3%marketbottom25%1.8%markettop25%5.0%industryaverage1.5%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: IDH's dividend (0.26%) isn’t notable compared to the bottom 25% of dividend payers in the UK market (1.83%).

High Dividend: IDH's dividend (0.26%) is low compared to the top 25% of dividend payers in the UK market (4.95%).


Stability and Growth of Payments

Stable Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are stable.

Growing Dividend: IDH is not paying a notable dividend for the UK market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: IDH is not paying a notable dividend for the UK market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of IDH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of Immunodiagnostic Systems Holdings's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Jaap Stuut (49yo)

2.2yrs

Tenure

UK£233,000

Compensation

Mr. Jaap Stuut has been the Chief Executive Officer of Immunodiagnostic Systems Holdings PLC since October 31, 2017. Mr. Stuut has been with the Immunodiagnostic Systems Holdings PLC since 2013 and was pre ...


CEO Compensation Analysis

Compensation vs Market: Jaap's total compensation ($USD302.59K) is about average for companies of similar size in the UK market ($USD326.78K).

Compensation vs Earnings: Jaap's compensation has been consistent with company performance over the past year.


Management Age and Tenure

4.0yrs

Average Tenure

49yo

Average Age

Experienced Management: IDH's management team is considered experienced (4 years average tenure).


Board Age and Tenure

4.2yrs

Average Tenure

53yo

Average Age

Experienced Board: IDH's board of directors are considered experienced (4.2 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Management Team

  • Ed Coombes (48yo)

    Head Of Business Development - Instrumentation

    • Rudolf Schemer (58yo)

      CEO of GeschTMaftsfuhrer at IDS GmbH Frankfurt & Country Manager of Germany Region

      • Tenure: 12.8yrs
    • Nicola Mitton

      Group HR Director

      • Paul Martin

        Group Finance Director

        • Tenure: 4yrs
        • Compensation: UK£229.00k
      • Jaap Stuut (49yo)

        CEO & Director

        • Tenure: 2.2yrs
        • Compensation: UK£233.00k

      Board Members

      • Burkhard Wittek (65yo)

        Non-Executive Chairman

        • Tenure: 5yrs
        • Compensation: UK£60.00k
      • Peter Kaspar

        Non-Executive Director

        • Tenure: 4.2yrs
        • Compensation: UK£30.00k
      • Peter Williamson (53yo)

        Non-Executive Director

        • Tenure: 4.6yrs
        • Compensation: UK£30.00k
      • Paul Martin

        Group Finance Director

        • Tenure: 4yrs
        • Compensation: UK£229.00k
      • Jaap Stuut (49yo)

        CEO & Director

        • Tenure: 2.2yrs
        • Compensation: UK£233.00k

      Company Information

      Immunodiagnostic Systems Holdings PLC's company bio, employee growth, exchange listings and data sources


      Key Information

      • Name: Immunodiagnostic Systems Holdings PLC
      • Ticker: IDH
      • Exchange: AIM
      • Founded: 1977
      • Industry: Health Care Equipment
      • Sector: Healthcare
      • Market Cap: UK£76.278m
      • Shares outstanding: 28.78m
      • Website: https://www.idsplc.com

      Number of Employees


      Location

      • Immunodiagnostic Systems Holdings PLC
      • Boldon Business Park
      • 10 Didcot Way
      • Boldon
      • Tyne and Wear
      • NE35 9PD
      • United Kingdom

      Listings

      TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
      IDHAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPDec 2004
      LWXDB (Deutsche Boerse AG)YesOrdinary SharesDEEURDec 2004

      Biography

      Immunodiagnostic Systems Holdings PLC develops, manufactures, and sells in-vitro diagnostic tests to the clinical laboratory market in the United Kingdom, the United States, Germany, France, and internationally. It develops, manufactures, and markets immunoassays and automated immunoanalyser technologies to provide diagnostic outcomes for patients. It offers IDS-iSYS multi-discipline automated systems, which is based on chemiluminescence and absorbency technology is used for immunoassay testing. The company provides its products and services for diagnosis of bone metabolism, calcium metabolism, hypertension, chronic kidney disease mineral bone disorder, growth, fertility, autoimmunity, infectious disease, sarcoidosis, and allergy. Immunodiagnostic Systems Holdings PLC was founded in 1977 and is headquartered in Boldon, the United Kingdom. 


      Company Analysis and Financial Data Status

      All financial data provided by Standard & Poor's Capital IQ.
      DataLast Updated (UTC time)
      Company Analysis2020/01/19 20:32
      End of Day Share Price2020/01/17 00:00
      Earnings2019/09/30
      Annual Earnings2019/03/31


      Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.